Oral News and Research

RSS

Merck, AiCuris enter licensing agreement for novel HCMV candidates

Merck, known as MSD outside the United States and Canada, and AiCuris today announced that they have entered into an exclusive worldwide licensing agreement for AiCuris' novel portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of HCMV infection in transplant recipients.

15 Oct 2012

Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX 1 and 4 inhibitor, GKT137831, will be presented at Kidney Week 2012.

15 Oct 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012

Contraceptive patch suppresses ovulation in obese, nonobese women

Use of a novel transdermal contraceptive patch suppresses ovulation in obese and nonobese women, research shows.

12 Oct 2012

Study compares two drug combinations for use as deep sedation during oral surgery

The ideal sedative for oral surgery should make the patient comfortable during the surgery and should wear off quickly enough that the patient can leave the dental chair soon after the procedure. Finding the best plan of anesthetic treatment is essential to the success of dental procedures such as the extraction of wisdom teeth.

12 Oct 2012

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Today Biogen Idec announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.

12 Oct 2012

Cardioviva can help fill the gap between diet, exercise and drugs

Over half (52 percent) of supplement users are concerned about their heart health and 73 percent express an interest in natural, clinically proven solutions for cholesterol reduction, according to market research conducted by Micropharma Limited, a pioneer in the development of innovative and effective probiotics.

12 Oct 2012

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

The American Association for Cancer Research will host the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research at the Hilton Anaheim from Oct. 16-19, 2012.

12 Oct 2012

Tourniquet timing alters foot surgery pain outcomes

The timing of thigh tourniquet application may affect pain control in patients undergoing forefoot surgery, research published in Foot and Ankle Surgery suggests.

11 Oct 2012

Tissue test detects oral cancer risk

A molecular diagnostic scoring system based on patients’ FOXM1-associated gene messenger RNA expression levels is able to quantitatively diagnose and stratify oral carcinoma and its aggressiveness, show UK and Norwegian study results.

11 Oct 2012

Catalent licenses NJIT’s taste-making technology to mask unpleasant and bitter medicines

Following a successful research collaboration with NJIT, Catalent Pharma Solutions of Somerset has announced that it has exclusively licensed innovative taste-making technology developed by NJIT Distinguished Professor Rajesh Dav-, who was the principal investigator of a research project funded by Catalent. The technology will mask the most challenging, unpleasant and bitter tasting pharmaceutical active ingredients.

11 Oct 2012

Salivary-biomarker approach can identify individuals at future risk of PTSD, depression

Each year, more than a million Americans are at-risk of developing serious mental health problems after experiencing a terrifying event or serious physical injury. Once manifested, these psychiatric illnesses, such as post-traumatic stress disorder and depression, can be extremely crippling and difficult to treat and are a leading cause of disability in civilian, military and minority populations.

10 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

According to the Centers for Disease Control (CDC), endometriosis, a gynecological disorder in which cells from the uterus lining grow in other areas of the body, is the number one reason for a hysterectomy in women ages 18-35. Current treatment options for endometriosis are severely limited by side effects of existing medications and surgical options have more risks. A nationwide clinical trial is testing an investigational drug as a potential new option for patients with moderate to severe pain from this disease.

9 Oct 2012

Best-practices protocol significantly reduces ventilator-associated pneumonia

An intensive care unit-initiated protocol implementing “best practices” significantly reduces ventilator-associated pneumonia, research shows.

8 Oct 2012

Combined medical–dental visits for infants could reduce Medicaid payouts

An office-based preventive oral health program has resulted in low monthly dental treatment rates for its infant-age Medicaid beneficiary participants, and reduced the likelihood of their hospitalization for dental matters, show US study results.

8 Oct 2012

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.

8 Oct 2012

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

GTx, Inc. announced today there will be two scientific poster presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function and quality of life in middle aged and elderly cancer patients.

8 Oct 2012

Department of Veterans Affairs implements pilot version of Diabetes Prevention Program

The Department of Veterans Affairs today announced the implementation of a pilot version of the Diabetes Prevention Program (DPP), a program being promoted nationally by the Centers for Disease Control and Prevention, aimed at reducing the number of Veterans who develop diabetes.

6 Oct 2012

Oral medication as effective as Botox injections for treating incontinence in women

Oral medication for treating a type of incontinence in women is roughly as effective as Botox injections to the bladder, reported researchers who conducted a National Institutes of Health clinical trials network study, with each form of treatment having benefits and limitations.

6 Oct 2012

Oral News and Research

Merck, AiCuris enter licensing agreement for novel HCMV candidates

Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Contraceptive patch suppresses ovulation in obese, nonobese women

Study compares two drug combinations for use as deep sedation during oral surgery

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Cardioviva can help fill the gap between diet, exercise and drugs

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

Tourniquet timing alters foot surgery pain outcomes

Tissue test detects oral cancer risk

Catalent licenses NJIT’s taste-making technology to mask unpleasant and bitter medicines

Salivary-biomarker approach can identify individuals at future risk of PTSD, depression

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

Best-practices protocol significantly reduces ventilator-associated pneumonia

Combined medical–dental visits for infants could reduce Medicaid payouts

Positive results from Cempra's IV solithromycin Phase 1 study

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

Department of Veterans Affairs implements pilot version of Diabetes Prevention Program

Oral medication as effective as Botox injections for treating incontinence in women

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News